Latest Benzoates Stories

SAN DIEGO and IRVINE, Calif., May 13, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today the acquisition of exclusive distribution rights from Samyang Biopharmaceuticals ("Samyang"), a South Korean corporation, to Cynviloq(TM) (marketed as Genexol-PM® in South Korea) in the 27 countries of European Union (EU). IGDRASOL had previously obtained the exclusive U.S. distribution rights to Cynviloq(TM) from Samyang, and with this agreement,...

BUFFALO, N.Y., May 6, 2013 /PRNewswire/ -- Kinex Pharmaceuticals and Zenith Technology Corporation, through its affiliate ZenRx, announced today the execution of a collaborative licensing agreement granting Zenith Technology commercial rights to Oraxol and Oratecan in New Zealand and Australia. ZenRx will provide an upfront payment, milestones and royalties. Importantly, Zenith Technology Corporation will commit a significant amount of resources to the Oraxol and Oratecan global...

EAST SETAUKET, N.Y., April 25, 2013 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. (LIXT), reported the start of a Phase I trial to determine the appropriate dose of its potentially first-in-class, anticancer compound, LB-100, when given alone and then when given in combination with docetaxel (Taxotere®). Details of the trial underway at an NCI-designated Comprehensive Cancer Center are available in the clinical trials registry: http://clinicaltrials.gov/show/NCT01837667. Dr....

IGDRASOL will present updates on its proprietary late clinical stage NBN-Pac formulations, including Cynviloq(TM), a paclitaxel nanoparticle, and the recently acquired IG-004, a vitamin E-based paclitaxel emulsion. Highlights of the findings include the studies and comparison of pharmacokinetic and pharmacodynamic properties as well as drug release characteristics to Abraxane®, an albumin-based paclitaxel nanoparticle (nab-paclitaxel). SAN DIEGO and FOUNTAIN VALLEY, Calif., April 8,...

IGDRASOL will present updates on Cynviloq(TM), its late clinical stage paclitaxel nanoparticle formulation. Highlights include the therapeutic evaluation of Cynviloq(TM) in poorly perfused tumors as well as the potential development of Cynviloq(TM)-based personalized paclitaxel cancer therapy. SAN DIEGO and FOUNTAIN VALLEY, Calif., March 31, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE) and IGDRASOL announced today that IGDRASOL will be presenting updates of its...

Transaction establishes a pipeline led by IGDRASOL's late clinical stage paclitaxel-loaded micellar product candidate and enables the combination of IGDRASOL's additional proprietary formulation technology with Sorrento's G-MAB® antibody libraries as a broad platform for next-generation targeted therapeutics. SAN DIEGO and FOUNTAIN VALLEY, Calif., March 7, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to...

redOrbit Staff & Wire Reports - Your Universe Online Students at one UK university will be using cocaine in the name of science – specifically, they will be participating in a clinical study to better understand how the substance impacts the human body. The research will be taking place at King’s College London, where hundreds of undergraduate students have received emails inviting them to participate in a study “involving nasal administration” of the Class A drug, London...

Challenge of initial stop by North Carolina drug crimes defense attorney Patrick Roberts of Roberts Law Group, PLLC, leads to dismissal of drug trafficking charges. Raleigh, NC (PRWEB) February 13, 2013 Raleigh criminal defense lawyer Patrick Roberts of Roberts Law Group, PLLC, in Raleigh, successfully argued for dismissal of drug charges after a routine traffic stop resulted in an illegal search of the defendant’s home. The client was facing up to 84 months in prison on cocaine...

EXTON, Pa., Jan. 10, 2013 /PRNewswire/ -- Morphotek(®) Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study found that farletuzumab in combination with carboplatin and a taxane did not meet the study's primary endpoint of progression-free...

Tokyo, Jan 11, 2013 - (JCN Newswire) - Eisai Co., Ltd. announced today the preliminary results of its global Phase III study (Study FAR 131, MORAb-003-004) of farletuzumab (MORAb-003), an investigational compound under development at its U.S. subsidiary, Morphotek, Inc., in patients with platinum-sensitive epithelial ovarian cancer in first relapse. The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study of 1,100...